Global Pets Internal Parasiticide Market Size By Type (Tablet, Powder), By Application (Dogs, Cats), By Region, And Segment Forecasts, 2023 to 2032

The Global Pets Internal Parasiticide Market was valued at USD 4.1 billion in 2023 and is projected to reach USD 7.3 billion by 2031, growing at a CAGR of 7.2% during the forecast period from 2023 to 2031. The increasing pet ownership worldwide, heightened awareness regarding animal health, and the prevalence of zoonotic diseases are major factors driving the market. Internal parasiticides play a critical role in preventing and controlling infestations caused by roundworms, hookworms, tapeworms, and other gastrointestinal parasites in pets, particularly dogs and cats. Advances in veterinary healthcare, the rise of e-commerce in pet product sales, and growing spending on pet wellness are bolstering market expansion.

Drivers:

1. Rising Pet Ownership and Humanization of Pets:

The global surge in pet adoption and the growing tendency to treat pets as family members have led to increased expenditure on pet healthcare. Owners are proactively seeking preventive solutions such as internal parasiticides to ensure their pets' well-being.

2. Growing Awareness of Zoonotic Parasites:

Internal parasites in pets pose health risks not only to the animals but also to humans. Rising awareness about zoonotic diseases is pushing owners and veterinary professionals toward routine use of internal parasiticides.

3. Advances in Veterinary Pharmaceuticals:

The development of broad-spectrum and long-acting internal parasiticides is improving treatment outcomes and compliance. Innovations such as chewable tablets, flavored medications, and combination therapies are making treatment more accessible and appealing to both pets and owners.

Restraints:

1. Regulatory Hurdles and Product Approval Timeframes:

The stringent regulatory frameworks for veterinary pharmaceuticals can delay product launches and limit market entry for smaller players. Complex approval processes and compliance requirements may restrain innovation.

2. Limited Access in Developing Regions:

Despite rising pet ownership in emerging markets, lack of access to veterinary healthcare services and lower awareness about internal parasites can inhibit market growth in those regions.

Opportunity:

1. Expansion of Online Veterinary Pharmacies:

E-commerce has revolutionized the pet care industry, offering convenience and broad reach for internal parasiticides. Online platforms present a strong growth opportunity by facilitating product availability and promoting preventive care.

2. Strategic Collaborations with Veterinary Clinics:

Partnerships between parasiticide manufacturers and veterinary chains offer mutual benefits such as enhanced customer education, higher compliance rates, and expanded product reach.

Market by System Type Insights:

Based on type, the Anthelmintic Tablets segment dominated the market in 2023. This segment is widely preferred for its convenience, precise dosing, and effectiveness against a broad spectrum of internal parasites. Meanwhile, the Spot-on Treatments segment is expected to grow at the highest CAGR due to ease of application and suitability for pets resistant to oral medication.

Market by End-use Insights:

The Household Pets segment accounted for the largest market share in 2023, driven by increased adoption of companion animals and regular preventive care routines among pet owners. The Veterinary Clinics segment is also expanding rapidly as pet owners increasingly rely on professionals for parasite management, diagnosis, and treatment plans.

Market by Regional Insights:

North America emerged as the largest market in 2023, underpinned by high pet ownership rates, advanced veterinary infrastructure, and awareness about pet health. However, Asia-Pacific is forecasted to witness the fastest growth due to rising disposable incomes, growing pet adoption, and expanding veterinary healthcare access in countries like China, India, and Southeast Asia.

Competitive Scenario:

Prominent players in the Global Pets Internal Parasiticide Market include Zoetis Inc., Elanco Animal Health Inc., Boehringer Ingelheim, Merck Animal Health, Virbac, Vetoquinol, Bayer AG (acquired by Elanco), Ceva Santé Animale, and Dechra Pharmaceuticals. These companies are focusing on expanding product portfolios, entering emerging markets, and investing in R&D to develop more effective and user-friendly parasiticides.

Scope of Work – Global Pets Internal Parasiticide Market

Key Market Developments:

2023: Zoetis launched a chewable broad-spectrum parasiticide targeting dogs, improving treatment compliance and user convenience.

2024: Boehringer Ingelheim expanded its NexGard product line with a long-acting internal parasiticide.

2025: Elanco introduced a dual-action tablet combining internal and external parasite protection, driving cross-category adoption among pet owners.

FAQs:

1) What is the current market size of the Global Pets Internal Parasiticide Market?

The market size was USD 4.1 billion in 2023.

2) What is the major growth driver of the Global Pets Internal Parasiticide Market?

The major growth driver is increasing global pet ownership and awareness of zoonotic internal parasites.

3) Which is the largest region during the forecast period in the Global Pets Internal Parasiticide Market?

North America is the largest region, while Asia-Pacific is expected to grow fastest.

4) Which segment accounted for the largest market share in Global Pets Internal Parasiticide Market?

The Anthelmintic Tablets segment held the largest share in 2023.

5) Who are the key market players in the Global Pets Internal Parasiticide Market?

Key players include Zoetis, Elanco, Boehringer Ingelheim, Merck Animal Health, Virbac, and Ceva Santé Animale.